IL2 and acute myeloid leukemia: A phase III trial of 320 AML patients in remission showed that treatment with histamine dihydrochloride and interleukin-2 (HDC/IL-2) significantly improved leukemia-free survival (LFS) versus standard of care in patients below 60 years of age [4].